Clinical Trials on Non-valvular Atrial Fibrillation (NVAF)

Total 14032 results

Bristol-Myers Squibb

Completed

A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan

Non-Valvular Atrial Fibrillation (NVAF)

Japan
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

Non-valvular Atrial Fibrillation (NVAF)

Japan
Bristol-Myers Squibb

Recruiting

A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation (PRESBUS)

Non-Valvular Atrial Fibrillation (NVAF)

Italy
Bristol-Myers Squibb

Withdrawn

Early Post-marketing Study of Eliquis (Apixaban)

Non-valvular Atrial Fibrillation (NVAF)

Mexico
Bayer

Completed

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin (RENOVATOR)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Abbott Medical Devices

Completed

AMPLATZER™ Cardiac Plug Observational Post-Approval Study (ACP China)

Non-valvular Atrial Fibrillation (NVAF)

China
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (XARENAL)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) (XARIN)

Non-valvular Atrial Fibrillation (NVAF)

India
Bayer
Janssen Research & Development, LLC

Completed

Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function (XARETO)

Non-valvular Atrial Fibrillation (NVAF)

Taiwan
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)

Non-valvular Atrial Fibrillation (NVAF) | Acute Coronary Syndrome (ACS)

China
Prof. Dr. med. Ingo Eitel

Recruiting

Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease (LAA-KIDNEY)

Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent

Germany
GWT-TUD GmbH
ClinStat GmbH

Completed

Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry (XARENO)

Chronic Kidney Disease (CKD) | Non-valvular Atrial Fibrillation (NVAF)

Germany, Austria, France, Belgium, Switzerland
University Hospital, Basel, Switzerland
Medtronic; Freiwillige Akademische Gesellschaft (FAG) Basel

Recruiting

The Basel CardioInsightTM - 3D Mapping Study (BigMap)

New-onset Atrial Fibrillation (NOAF)

Switzerland
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb

Completed

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry

Non-valvular Atrial Fibrillation

United States
Boston Scientific Corporation

Recruiting

Watchman FLX Pro CT Pilot Study

Non-valvular Atrial Fibrillation (AF)

Denmark
Xijing Hospital
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Not yet recruiting

Registry to Evaluate Chinese Real-World Clinical Outcomes in Patients With AF Using the WATCHMAN Left Atrial Appendage Closure Technology (RECORD)

Non-valvular Atrial Fibrillation

China
Bayer
Janssen Research & Development, LLC

Completed

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

Non-valvular Atrial Fibrillation

Italy
Daiichi Sankyo, Inc.
Daiichi Sankyo (China) Holdings Co., Ltd.

Active, not recruiting

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China (ETNA-AF-CHINA)

Non-valvular Atrial Fibrillation

China
Saint Luke's Health System
Bristol-Myers Squibb; AliveCor

Completed

Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)

Non-valvular Atrial Fibrillation

United States
Pfizer

Completed

Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding

Non-valvular Atrial Fibrillation

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists (ANTENNA)

Non-Valvular Atrial Fibrillation

United Kingdom
Bristol-Myers Squibb

Completed

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) (AEGEAN)

Non-valvular Atrial Fibrillation

Belgium, France, Italy, Spain, Switzerland, Germany, United Kingdom
Bristol-Myers Squibb
IMS Health; OXON Epidemiology

Completed

Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2 (REACT-AF2)

Non-valvular Atrial Fibrillation
Bristol-Myers Squibb

Completed

Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela

Non-Valvular Atrial Fibrillation
Cardia Inc.

Unknown

Canadian Left Atrial Appendage Closure Study (CLASS)

Non-Valvular Atrial Fibrillation | Left Atrial Appendage

Canada
Abbott Medical Devices

Recruiting

Amplatzer Amulet China Post Market Study (PMS)

Non-Valvular Atrial Fibrillation

China
Conformal Medical, Inc

Completed

The Conformal Prague Study

Non-valvular Atrial Fibrillation

Czechia
University Hospital, Montpellier

Completed

Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program (MONACO)

Non-valvular Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Terminated

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients. (PROTECT-AF)

Non-valvular Atrial Fibrillation

Norway
Pfizer

Completed

Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation (CER3)

Non-valvular Atrial Fibrillation

Japan
China National Center for Cardiovascular Diseases
Chinese Academy of Medical Sciences, Fuwai Hospital

Recruiting

Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Non-Valvular Atrial Fibrillation

China
Conformal Medical, Inc
Yale Cardiovascular Research Group

Active, not recruiting

The CONFORMAL Early Feasibility Study

Non-valvular Atrial Fibrillation

United States
Bristol-Myers Squibb

Completed

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation (ARISTOPHANES)

Non-Valvular Atrial Fibrillation

United States
Laminar, Inc.

Active, not recruiting

An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

Non-valvular Atrial Fibrillation

United States
Daiichi Sankyo, Inc.
Daiichi Sankyo Deutschland GmbH

Completed

Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENCOURAGE-AF)

Non-valvular Atrial Fibrillation

Germany
Bristol-Myers Squibb

Withdrawn

Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)

Non-valvular Atrial Fibrillation

United States
Boston Scientific Corporation
Iqvia Pty Ltd; Premier Research Group plc

Completed

Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)

Non-valvular Atrial Fibrillation

Ireland, Germany, Denmark, France, Spain, United Kingdom, Italy, Netherlands, Poland
Bristol-Myers Squibb
Pfizer

Withdrawn

Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation

Non-valvular Atrial Fibrillation
Scripps Health
Daiichi Sankyo, Inc.

Unknown

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

Non-Valvular Atrial Fibrillation | Left Atrial Appendage Closure

United States
Tohoku University

Unknown

Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation (EXPAND)

Non-valvular Atrial Fibrillation

Japan
Beijing Friendship Hospital

Recruiting

The Impact of Frailty on Thrombosis of Elderly Patients With NVAF （FTE-NVAF）

Non-valvular Atrial Fibrillation, Elderly, Frailty, Thrombosis

China
University Hospital, Essen

Completed

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA (PRODAST)

Brain Ischemia With Non-valvular Atrial Fibrillation | Transient Ischemic Attack With Non-valvular Atrial Fibrillation

Germany
Eclipse Medical Ltd.
KCRI

Recruiting

Evaluation od Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk (Omega)

Non-Valvular Atrial Fibrillation

Denmark, Germany, Italy, Spain, United Kingdom
Assistance Publique - Hôpitaux de Paris

Unknown

Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF) (Presage-Aco)

Non Valvular Atrial Fibrillation (nv AF)
Coherex Medical

Terminated

WAVECREST Post Market Clinical Follow-Up (PMCF) Study

Non-valvular Atrial Fibrillation

Belgium
Boston Scientific Corporation

Active, not recruiting

Observe the Safety and Effectiveness of the WATCHMAN FLX™ for Subjects in Hong Kong

Non-valvular Atrial Fibrillation

China
Second Affiliated Hospital, School of Medicine,...
The First Affiliated Hospital of Nanchang University; LanZhou University; The... and other collaborators

Completed

LAMax Vs. Watchman LAAC Device for Subjects With Non-valvular AF to Reduce the Risk of Stroke

Non-valvular Atrial Fibrillation

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation

Non-valvular Atrial Fibrillation

China
Pfizer

Completed

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Non-valvular Atrial Fibrillation

Japan
Bayer

Completed

A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention. (BELANCE)

Non-Valvular Atrial Fibrillation

Belgium

3

Subscribe